Published in Eur J Pharmacol on May 02, 2005
Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res (2006) 1.91
Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol (2010) 1.53
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell (2012) 1.44
The functional role of Notch signaling in human gliomas. Neuro Oncol (2009) 1.39
Involvement of notch signaling in wound healing. PLoS One (2007) 1.35
Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol (2012) 1.20
The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med (2009) 1.07
Notch inhibitors as a new tool in the war on cancer: a pathway to watch. Curr Pharm Biotechnol (2009) 1.00
Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol (2009) 0.99
Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res (2008) 0.99
Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology (2010) 0.93
Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. PLoS One (2011) 0.89
Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J (2009) 0.86
Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology. Semin Cancer Biol (2007) 0.82
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget (2016) 0.78
Interactions between morphine and nitric oxide in various organs. J Anesth (2009) 0.78
Oncogenesis and cancer stem cells: current opinions and future directions. J Cell Mol Med (2009) 0.78
Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int (2016) 0.77
Statistical platform to discern spatial and temporal coordination of endothelial sprouting. Integr Biol (Camb) (2012) 0.76
Early neurovascular dysfunction in a transgenic rat model of Alzheimer's disease. Sci Rep (2017) 0.75
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. Physiology (Bethesda) (2017) 0.75
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci (2002) 1.97
Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. Int J Geriatr Psychiatry (2009) 1.82
Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord (2009) 1.43
Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.25
Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann Neurol (2014) 1.23
CD40 is expressed and functional on neuronal cells. EMBO J (2002) 1.19
Inhibition of angiogenesis by Abeta peptides. Angiogenesis (2004) 1.19
Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res (2003) 1.16
Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol (2002) 1.13
Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes. J Neurotrauma (2012) 1.11
Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett (2006) 1.11
Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett (2004) 1.10
Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem (2009) 1.06
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res (2004) 1.05
Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. Eur J Pharmacol (2012) 1.05
Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging (2009) 1.04
Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol (2009) 1.03
Recovery potential after postnatal shoulder paralysis. An animal model of neonatal brachial plexus palsy. J Bone Joint Surg Am (2009) 1.00
Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol (2011) 1.00
Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med (2010) 0.98
Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain (2007) 0.96
The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett (2007) 0.95
p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res (2002) 0.95
Musculoskeletal deformities secondary to neurotomy of the superior trunk of the brachial plexus in neonatal mice. J Orthop Res (2010) 0.95
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res (2004) 0.94
High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients. Mol Med (2009) 0.94
Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier. J Mol Neurosci (2012) 0.93
Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells. Brain Res Mol Brain Res (2005) 0.92
Genomic regulation after CD40 stimulation in microglia: relevance to Alzheimer's disease. Brain Res Mol Brain Res (2005) 0.91
Serum beta-amyloid correlates with neuropsychological impairment. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2009) 0.91
Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol (2006) 0.91
Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis (2002) 0.89
Apolipoprotein E polymorphism and age of onset for Alzheimer's disease in a bi-ethnic sample. Int Psychogeriatr (2004) 0.89
Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol (2011) 0.89
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial. Int J Geriatr Psychiatry (2011) 0.88
Primary malignancy in crossed fused ectopic kidney. Abdom Imaging (2012) 0.88
A 6.5-cm pseudoaneurysm of the superior mesenteric artery managed by primary surgical repair. Vascular (2011) 0.88
Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine (2008) 0.87
Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat (2002) 0.87
Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol (2006) 0.87
Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med (2009) 0.87
Increased TNFalpha production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neurosci Lett (2003) 0.86
Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chem Biol (2008) 0.86
CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. J Neuroimmunol (2002) 0.86
Neuropsychological comparison of Alzheimer's disease and dementia with lewy bodies. Dement Geriatr Cogn Disord (2006) 0.86
Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Cytotechnology (2010) 0.85
Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res (2004) 0.84
A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis (2012) 0.84
No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly. Int J Geriatr Psychiatry (2004) 0.83
Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease. J Neurosci (2010) 0.83
Glial cytoplasmic inclusions in neurologically normal elderly: prodromal multiple system atrophy? Acta Neuropathol (2008) 0.83
Apolipoprotein E and cognition in community-based samples of African Americans and Caucasians. Ethn Dis (2006) 0.83
The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett (2005) 0.83
CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. J Neuroinflammation (2006) 0.82
Chronic elevation of phosphocholine containing lipids in mice exposed to Gulf War agents pyridostigmine bromide and permethrin. Neurotoxicol Teratol (2013) 0.82
Differences in executive functioning between Alzheimer's disease and subcortical ischemic vascular dementia. J Clin Exp Neuropsychol (2002) 0.82
Improving image analysis in 2DGE-based redox proteomics by labeling protein carbonyl with fluorescent hydroxylamine. Biol Proced Online (2007) 0.82
Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease. Cytokine (2010) 0.82
Identification of plasma biomarkers of TBI outcome using proteomic approaches in an APOE mouse model. J Neurotrauma (2011) 0.81
Proteomic CNS profile of delayed cognitive impairment in mice exposed to Gulf War agents. Neuromolecular Med (2011) 0.81
Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid (2008) 0.81
Repetitive mild traumatic brain injury causes optic nerve and retinal damage in a mouse model. J Neuropathol Exp Neurol (2014) 0.80
CD40 promotion of amyloid beta production occurs via the NF-kappaB pathway. Eur J Neurosci (2007) 0.80
Apolipoprotein E isoform-specific effects on lipoprotein receptor processing. Neuromolecular Med (2014) 0.79
Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. Int J Alzheimers Dis (2011) 0.78
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings. J Geriatr Psychiatry Neurol (2006) 0.78
Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample. Alzheimer Dis Assoc Disord (2002) 0.78
Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. Bioorg Med Chem (2009) 0.78
CliniProteus: A flexible clinical trials information management system. Bioinformation (2007) 0.78
Splenic injury after colonoscopy requiring splenectomy. BMJ Case Rep (2013) 0.77
Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci (2013) 0.77